The trial met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001). The observed 50 percent reduction in fractures between
The drug development and license agreement between Transposagen and Janssen, which was announced in November of 2014, has been transferred to Poseida. The three-year drug development partnership and
These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago. Veliparib is an investigational oral poly (adenosine diphosphate
This is the first combination of BRAF/MEK inhibitors to demonstrate a statistically significant overall survival benefit for this patient population in two Phase III studies. Results are being
ASP2215 is a receptor tyrosine kinase inhibitor of FLT3 and AXL, which are involved in the growth of cancer cells. ASP2215 demonstrated inhibitory activity against FLT3 internal tandem
The trial will evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Lilly’s vascular endothelial growth factor (VEGF) Receptor 2
Argatroban Injection is an anticoagulant indicated for prophylaxis or treatment of thrombosis in adult patients with heparin induced thrombocytopenia (HIT), or as an anticoagulant in adult patients with
Results from the Phase 3 PALOMA-3 study will be featured today in a press briefing during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Cerdulatinib is an oral, dual Syk-JAK kinase inhibitor that Portola is developing to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded
Cannabics’ team of scientists has developed a high throughput screening system which is specifically designed to give personalized antitumor treatments to cancer patients. In this proprietary system, biopsies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.